Future prospects for an Innovative Medicines Fund for England
Cancer Drugs Fund, CDF, Innovative Medicines Fund, NHS, UK
0 Comment
CDF
New price gets Clovis’ PARP inhibitor on the CDF
CDF, Clovis, Clovis Oncology, ovarian cancer, PARP inhibitor, Rubraca
0 Comment
NICE’s track record in cancer drugs: the impact of the CDF and interim funding
cancer, Cancer Drugs Fund, CDF, HTA, NICE, NICE numbers at 20
0 Comment
02/11/2016
Finding a cure: Getting the best Brexit deal for Britain’s life sciences
ABPI, Brexit, cancer, CASMI, CDF, debate, Dorrell, exclusive, McFarlane, NICE, quintilesIMS, Report, webinar
1 Comment
A novel UK approach to cancer access: yes, no, or maybe?
Cancer Drugs Fund, CDF, market access, NHS, patients, pharma, Real World Evidence, RWE
0 Comment
Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
England’s ‘world-first’ cancer database – can it deliver on its promise?
ABPI, cancer, cancer database, CDF, Public Health England, SACT
0 Comment
The world’s first national database of cancer treatment outcomes has been launched in England.
What doctors say about changes to the Cancer Drugs Fund
cancer, Cancer Drugs Fund, CDF, HCP, new CDF, NHS, NICE, social media
0 Comment
Assessing HCPs’ social media comments about the new approach to cancer drug funding.
NICE says no to liver cancer drug Nexavar
Bayer, CDF, Liver cancer, Nexavar, NICE
0 Comment
Liver cancer treatment latest earmarked for removal from CDF
1 2